Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Current assets
Cash and cash equivalents	$ 81,331	$ 87,928
Marketable securities	208,619	203,509
Prepaid expenses and other current assets	18,965	2,452
Total current assets	308,915	293,889
Long-term assets
Property and equipment, net	173	186
Operating lease right-of-use assets	2,603	2,798
Intangible assets, net	6,318	6,805
Long-term marketable securities	0	27,211
Other long-term assets	83	83
Total assets	318,092	330,972
Current liabilities
Accounts payable	5,483	8,882
Accrued compensation	4,277	4,776
Accrued clinical trial site costs	1,824	1,826
Operating lease liabilities	597	526
Accrued interest payable	423
Other current liabilities	3,127	2,737
Total current liabilities	15,731	18,747
Long-term liabilities
Contingent liability for Essentialis purchase price	17,758	14,791
Long-term debt, net	49,836	49,828
Long-term lease liabilities	2,361	2,472
Other long-term liabilities	145	21
Total liabilities	85,831	85,859
Commitments and contingencies (Note 5)
Stockholders’ equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 shares authorized, 48,527,469 and 45,703,811 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	49	46
Additional paid-in-capital	728,019	696,966
Accumulated other comprehensive gain	226	361
Accumulated deficit	(496,033)	(452,260)
Total stockholders’ equity	232,261	245,113
Total liabilities and stockholders’ equity	$ 318,092	$ 330,972